Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
ENANTA PHARMACEUTICALS INC reported twelve months ended September 30, 2022 results: revenue $86.2 million, net income Net loss was $121.8 million, EPS loss of $5.91 per diluted common share. Guidance initiated.
- Period
- twelve months ended September 30, 2022
- Revenue
- $86.2 million
- Net income
- Net loss was $121.8 million
- EPS
- loss of $5.91 per diluted common share
- Guidance
- initiated
- Result
- reported results
Exact text from the filing
For the twelve months ended September 30, 2022, total revenue was $86.2 million compared to $97.1 million for the same period in 2021. Research and development expenses were $34.8 million for the three months ended September 30, 2022, compared to $48.9 million for the three months ended September 30, 2021. For the twelve months ended September 30, 2022, research and development expenses were $164.5 million compared to $174.1 million in 2021. The decreases in both periods were due to the timing and scope of the company’s clinical trials. General and administrative expenses totaled $12.6 million for the three months ended September 30, 2022, compared to $8.4 million for the three months ended September 30, 2021. For the twelve months ended September 30, 2022, general and administrative expenses were $45.5 million compared to $32.5 million in 2021. The increases in both periods were due primarily to additional headcount and stock compensation expense. Enanta recorded an income tax expense
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
ENANTA PHARMACEUTICALS INC reported three months ended September 30, 2022 results: revenue $20.3 million, net income Net loss was $26.3 million, EPS loss of $1.27 per diluted common share. Guidance initiated.
- Period
- three months ended September 30, 2022
- Revenue
- $20.3 million
- Net income
- Net loss was $26.3 million
- EPS
- loss of $1.27 per diluted common share
- Guidance
- initiated
- Result
- reported results
Exact text from the filing
Total revenue of $20.3 million for the three months ended September 30, 2022, consisted of royalty revenue derived from worldwide net sales of AbbVie’s hepatitis C virus (HCV) regimen MAVYRET®/MAVIRET®, compared to royalty revenue of $23.6 million for the three months ended September 30, 2021. For the twelve months ended September 30, 2022, total revenue was $86.2 million compared to $97.1 million for the same period in 2021. Research and development expenses were $34.8 million for the three months ended September 30, 2022, compared to $48.9 million for the three months ended September 30, 2021. For the twelve months ended September 30, 2022, research and development expenses were $164.5 million compared to $174.1 million in 2021. The decreases in both periods were due to the timing and scope of the company’s clinical trials. General and administrative expenses totaled $12.6 million for the three months ended September 30, 2022, compared to $8.4 million for the three months ended Septe
View on SEC.gov